Hem › Atopisk dermatit (eksem) › Alabama
Kliniska studier för Atopisk dermatit (eksem) i Alabama
9 studier för Atopisk dermatit (eksem) söker deltagare vid platser i Alabama.
Städer i Alabama
Officiell studietext (engelska)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Cahaba Dermatology & Skin Health Center- Site Number : 8400006, Birmingham
- River Region Dermatology and Laser- Site Number : 8400041, Montgomery
RekryterarObservationsstudie
Ålder 12 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Birmingham
- Novartis Investigative Site, Birmingham
RekryterarFas 2
Ålder 18 till 100 · Alla kön · Uppdaterad 28 sep. 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Birmingham
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 25 sep. 2026 · NCT07298395First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Cahaba Dermatology & Skin Health Center, LLC, Birmingham
RekryterarFas 1Friska volontärer välkomna
Ålder 18 till 65 · Alla kön · Uppdaterad 25 sep. 2026 · NCT07527923A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Cahaba Dermatology & Skin Health Center, Birmingham
RekryterarFas 3
Ålder 2 till 11 · Alla kön · Uppdaterad 25 sep. 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- AllerVie Clinical Research, Birmingham
- Cahaba Dermatology and Skin Health Center, Birmingham
RekryterarFas 2
Ålder 18 till 65 · Alla kön · Uppdaterad 28 aug. 2026 · NCT07599813A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Birmingham
RekryterarFas 3
6 Months – 11 Years · Alla kön · Uppdaterad 7 juli 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Cahaba Dermatology & Skin Health Center /ID# 263855, Birmingham
RekryterarFas 3
Ålder 18 till 63 · Alla kön · Uppdaterad 6 juli 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Allervie Clinical Research, Birmingham
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 4 maj 2026 · NCT05995964Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.